Zheng Quan Zhi Xing·2025-08-22 14:17Core Viewpoint - The company has established a long-term incentive mechanism to ensure the successful implementation of the 2025 A-share option plan, aiming to enhance management performance and maximize shareholder interests [1][2]. Group 1: Assessment Objectives and Principles - The purpose of the assessment is to improve corporate governance and establish a long-term incentive mechanism to ensure the achievement of the company's strategic and operational goals by 2025 [1]. - The assessment must adhere to principles of fairness, openness, and impartiality, linking the A-share option plan closely with the performance and contributions of the incentivized individuals [1][2]. Group 2: Assessment Scope and Organization - The assessment applies to all individuals participating in the 2025 A-share option plan [1]. - The company's Board of Directors' Compensation and Assessment Committee will lead and organize the assessment work [1]. Group 3: Assessment Indicators and Standards - The assessment will evaluate the company's financial performance indicators annually, focusing on "net profit attributable to shareholders" and "revenue from innovative drugs" [1][2]. - Specific targets for the assessment indicators include a net profit target of 33.2 billion RMB for the first year, increasing to 39.6 billion RMB and 47.7 billion RMB in subsequent years [2][3]. Group 4: Assessment Period and Frequency - The assessment period spans from 2025 to 2027, with evaluations conducted annually [3][4]. Group 5: Assessment Procedures and Results Management - The Human Resources Department, under the guidance of the Compensation and Assessment Committee, is responsible for the assessment process and maintaining the results [4]. - Incentivized individuals have the right to understand their assessment results and can appeal if they disagree with the evaluations, following the established procedures [4].